TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05064072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water-based barrier tape
Description: The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrocolloid barrier tape
Description: As for experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube. The hydrocolloid barrier tape, which was cut and shaped appropriately beforehand, will be applied to the area in order to stabilize the nasogastric tube and the tube will be stabilized with silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the hydrocolloid barrier tape, the pain felt by the infants evaluated with Neonatal Infant Pain Scale and the score recorded in the chart. Since the hydrocolloid barrier tape can stay on the skin for 7 days and the assessment of the pain realized in 7th day and noted down to the chart. Pain score evaluated in 7th day 3 min. before procedure, during and 3 min after procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silk tape
Description: The silk tape used in clinic routinely will be used for control group infants to fix the nasogastric tube without any barrier. The silk tape will be 5cm long and it will be changed in every 24 hours. Following the removal of silk tape on the silk tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure
Study: NCT06439888

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Standard of Care, planned over 1 or 2 weeks, every lesions must be irradiated

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Standard of Care, planned over 1 or 2 weeks, every lesions must be irradiated

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Standard of Care, planned over 1 or 2 weeks, every lesions must be irradiated
Study: NCT06138444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional beverages from the submerged fermentation of Cordyceps militaris
Description: The Cordyceps militaris submerged fermentation in fruit juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional beverages from the submerged fermentation of Cordyceps militaris
Description: The Cordyceps militaris submerged fermentation in fruit juice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fruit juice
Description: Fruit juice is used as a placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fruit juice
Description: Fruit juice is used as a placebo.
Study: NCT06301724

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT04503161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duragen with Collagen Hydrodel and ASCs
Description: Duragen combined with collagen hydrogel and patient's stem cells
Study: NCT05967546

Intervention type: OTHER
Intervention: Observational
Description: No interventions will be given to patients.
Study: NCT06216782

Intervention type: OTHER
Intervention: Non-intervention
Description: Non-intervention

Intervention type: OTHER
Intervention: Non-intervention
Description: Non-intervention
Study: NCT04572867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquapheresis
Description: The Aquadex FlexFlow® Fluid Removal System (from CHF Solutions™, Minneapolis, MN) is an FDA approved device that provides mechanical isosmotic fluid removal in volume-overloaded CHF patients via veno-venous ultrafiltration, and has been used in patients with congestive heart failure refractory to diuretics, it should be considered standard of care also. This study is using it in a randomized, controlled study in the Outpatient setting. The Aquadex FlexFlow® Fluid Removal System is a dual rotary pump device used with a sterile, single-use UF 500 Blood Circuit Set. Blood withdrawal is usually from a peripheral arm vein (such as the antecubital vein), using a 16 or 18- gauge, 3.5 cm catheter (similar to a standard IV catheter). A similar IV catheter is used for blood return via a second peripheral vein (typically in the forearm).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Diuretics
Description: Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR\< 2.0, or 5mg PO if Cr \> 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
Study: NCT04913506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Mirror
Description: For 30 minutes, ROM exercises will be applied to the solid upper extremity in all directions in front of a real mirror by the practitioner. (3 weeks, 5 days a week, 15 sessions in total)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group NMES
Description: NMES will be applied to the hemiplegic arm(deltoid, elbow extensors and forearm) for 30 minutes by the practitioner (3 weeks, 5 days a week, 15 sessions in total)
Study: NCT04811443

Intervention type: DRUG
Intervention: Empegfilgrastim
Description: Extimia®
Study: NCT05293444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrine
Description: 400 ml at 10PM night before surgery(12.5g/100ml) 200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery.
Study: NCT04913506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Mirror+NMES
Description: The practitioner will be synchronized with visual or auditory stimuli, and ROM exercises in all directions in front of the real mirror for 30 minutes, and NMES therapy for 30 minutes on the paretic upper extremity will be applied together. (3 weeks, 5 days a week, 15 sessions in total)
Study: NCT05293444

Intervention type: OTHER
Group type: OTHER
Intervention: overnight fasting
Description: no intervention
Study: NCT06142838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community pharmacist intervention
Description: The community pharmacist intervention comprises 2 parts: (1) first prescription counseling (oral and written information), and (2) a follow-up consultation (by telephone or in person) 7-14 days later, to identify problems with adherence/treatment
Study: NCT05681455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation NESA NXSIGNAL® device
Description: Good positioning of the NXSIGNAL® device, as well as proper programming, is of vital importance for the achievement of the objective. General guidelines will be established, which should always be followed with the application of NESA microcurrents, and specific guidelines for this particular study, in order to obtain as homogeneous a sample as possible and to bring the device programming as close as possible to the objective to be pursued in the clinical trial. General guidelines for the application of XSIGNAL®.~The skin should be clean, free of creams and grease, so it will be necessary to clean with alcohol or similar. The placement of the gloves and socks of the device should follow the established protocols, paying attention to the location of each semielectrode in its anatomical position. The device has a color system to determine the location of each wire.~The directional electrode will be placed in the cervical area at the superficial level between C6 and C7.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromodulation NESA NXSIGNAL® device
Description: Good positioning of the NXSIGNAL® device, as well as proper programming, is of vital importance for the achievement of the objective. General guidelines will be established, which should always be followed with the application of NESA microcurrents, and specific guidelines for this particular study, in order to obtain as homogeneous a sample as possible and to bring the device programming as close as possible to the objective to be pursued in the clinical trial. General guidelines for the application of XSIGNAL®.~The skin should be clean, free of creams and grease, so it will be necessary to clean with alcohol or similar. The placement of the gloves and socks of the device should follow the established protocols, paying attention to the location of each semielectrode in its anatomical position. The device has a color system to determine the location of each wire.~The directional electrode will be placed in the cervical area at the superficial level between C6 and C7.
Study: NCT05508854

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: prenatal genetic counselling
Description: Prenatal genetic counseling is a consultancy service that covers the evaluation of the risk status of the baby in the mother's womb in terms of genetic diseases, the tests and risks that can be done for the diagnosis of the disease, the test results and information about the disease in case of illness and the presentation of options.
Study: NCT04535999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab Auto-Injector
Description: 300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)
Study: NCT04817345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Subcutaneous
Study: NCT05628506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium iodide
Description: Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.
Study: NCT06067776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given PO
Study: NCT05154136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Capsule
Study: NCT04788797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolyl Endopeptidase
Description: Two capsules three times a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules three times a day
Study: NCT05452954

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief behavioral parent training
Description: In the newly developed intervention, both stimulus control and contingency management techniques will be offered in a brief behavioral parent training consisting of two intervention sessions and one booster session.
Study: NCT05536089

Intervention type: DIAGNOSTIC_TEST
Intervention: a multi-locus blood-based assay
Description: Colorectal tumor-specific plasma ctDNA methylation markers detection

Intervention type: DIAGNOSTIC_TEST
Intervention: a multi-locus blood-based assay
Description: Colorectal tumor-specific plasma ctDNA methylation markers detection
Study: NCT06487702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium
Description: Fruquintinib administration for 2 weeks followed by 1-week break~Candonilimab：10 mg/kg，D1，Q3W；~Tegafur，Gimeracil and Oteracil Potassium：30mg BID for body surface area \< 1.25 m2; 40mg BID for body surface area of 1.25-1.5 m2; and 50mg BID for body surface area \>1.5 m2; D1-14, q3w
Study: NCT05955950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude list
Description: Participants must to write 3-5 words a day for 14 days about aspects of their daily experience that they are grateful for.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: List of any event
Description: Participants must to write 3-5 words a day for 14 days about events of your own choosing that impressed the participant during the day, whether positive or negative.
Study: NCT06647069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody
Study: NCT04828109

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Use of any virtual reality experiences available

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Use of any virtual reality experiences available

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Use of a Fitbit wearable activity device to track daily step goals.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Use of a Fitbit wearable activity device to track daily step goals.
Study: NCT05066022

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT0590 CAR T Cells
Description: Dose-escalated CAR T cells infusion
Study: NCT04874259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Living donor liver transplantation
Description: Living donor liver transplantation
Study: NCT04903080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2 Specific CAR T Cell
Description: HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2 Specific CAR T Cell
Description: HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.
Study: NCT05714072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 10mg BID or 15mg BID
Study: NCT05453630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Patients will receive navigation from a trained lay navigator at a community-based nonprofit organization that supports access to high quality healthcare. The patient navigator will work with patients to schedule their colonoscopy and identify, explore, and overcome barriers. They will educate patients about the colonoscopy procedure and preparation, provide resources, and coach and motivate patients.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care Control
Description: Educational brochure about colonoscopy
Study: NCT05714072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 50, 100 and 150 mg
Study: NCT05923294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap with connective tissue graft
Description: In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap with connective tissue graft
Description: In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area.
Study: NCT06363890

Intervention type: DIAGNOSTIC_TEST
Intervention: TAQMan Array Card
Description: Real time PCR test to detect diarrheal pathogens.
Study: NCT04677660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-919
Description: TAK-919 intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intramuscular injection
Study: NCT04882644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption three times per week for 60 min/session (including 5 min warm-up and 5 min cool down) with treadmills, ellipticals, and rowing machine. The subjects attend health education sessions (eg, general health knowledge of NAFLD and metabolic diseases, and elements of a healthy lifestyle) monthly in the 12 months.
Study: NCT06647069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody
Study: NCT04606316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab-Placebo
Description: Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
Study: NCT05606900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: addiction-focused eye movements desensitization and reprocessing (AF-EMDR)
Description: AF-EMDR includes desensitization and functional reprocessing of the targeted memory or the moment with lateral eye movements. In each session of the psychotherapy, which will be applied as 3 sessions, a memory or a moment that causes alcohol craving will be practised. The processing will continue until the patient becomes desensitized to the memory or the moment that cause the craving. In the first session, a memory of craving will be discussed, in the second session a current trigger that causes craving, and in the third session, a moment that is thought to cause craving in the future will be focused.
Study: NCT06356532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive care unit diary
Description: The intensive care unit diary is a notebook provided to patients during their stay in the intensive care unit, allowing them to record all events that occur during this period. Patients are encouraged to freely write about their experiences, which may include details about their treatment progress, daily activities, visits from family members, and other relevant aspects of their stay.
Study: NCT05940740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colorectal-Mobile application
Description: The use of Colorectal-Mobile application by the patients on a daily basis by the researcher will be monitored remotely via the management platform of the usage status of the mobile health application.
Study: NCT06459856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balloon blowing
Description: Ask the patient to take in a deep breath; steadily and slowly blow up the huge balloon. See the balloon getting bigger, and bigger. Now ask the patient to close the eyes and imagine the balloon floating into the air. Let the patient continue blowing of balloons until he or she gets relaxed and calm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percussion
Description: Percussion is a technique involving rhythmic tapping or clapping on the chest or back, serves as a means to move and loosen retained secretions within the airways. This mechanical intervention helps in removing mucus from the bronchial walls, and facilitates its expectoration and clearance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percussion
Description: Percussion is a technique involving rhythmic tapping or clapping on the chest or back, serves as a means to move and loosen retained secretions within the airways. This mechanical intervention helps in removing mucus from the bronchial walls, and facilitates its expectoration and clearance
Study: NCT05612984

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Calcium aspirin multiple micronutrients
Description: Women randomized to CAMMS will receive weekly blister cards containing all 3 components: 1 81 mg aspirin tablet, 1 UNIMMAP MMS, and 1 500-mg elemental calcium tablets. Blister packages will be labeled with times of day and days of week when tablets are to be taken. 4 weekly blister cards will be packaged in one unit box.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron-folic Acid
Description: Women randomized to IFA will receive monthly (28-day) blister cards containing containing 1 combined IFA tablet to be taken each day. 1 4-weekly blister card will be packaged in one unit box.
Study: NCT04477668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helmet non-invasive ventilation
Description: Patients will be allocated to helmet non-invasive ventilation